We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis.
- Authors
Panigrahy, Dipak; Singer, Samuel; Shen, Lucy Q; Butterfield, Catherine E; Freedman, Deborah A; Chen, Emy J; Moses, Marsha A; Kilroy, Susan; Duensing, Stefan; Fletcher, Christopher; Fletcher, Jonathan A; Hlatky, Lynn; Hahnfeldt, Philip; Folkman, Judah; Kaipainen, Arja
- Abstract
Several drugs approved for a variety of indications have been shown to exhibit antiangiogenic effects. Our study focuses on the PPARgamma ligand rosiglitazone, a compound widely used in the treatment of type 2 diabetes. We demonstrate, for the first time to our knowledge, that PPARgamma is highly expressed in tumor endothelium and is activated by rosiglitazone in cultured endothelial cells. Furthermore, we show that rosiglitazone suppresses primary tumor growth and metastasis by both direct and indirect antiangiogenic effects. Rosiglitazone inhibits bovine capillary endothelial cell but not tumor cell proliferation at low doses in vitro and decreases VEGF production by tumor cells. In our in vivo studies, rosiglitazone suppresses angiogenesis in the chick chorioallantoic membrane, in the avascular cornea, and in a variety of primary tumors. These results suggest that PPARgamma ligands may be useful in treating angiogenic diseases such as cancer by inhibiting angiogenesis.
- Publication
The Journal of clinical investigation, 2002, Vol 110, Issue 7, p923
- ISSN
0021-9738
- Publication type
Journal Article
- DOI
10.1172/JCI15634